CLH Stock Chart & Stats
€202.40
€2.10(1.05%)
At close: 4:00 PM EDT
€202.40
€2.10(1.05%)
Day’s Range― - ―
52-Week Range€124.60 - €210.30
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€47.16B
Enterprise Value€55.01K
Total Cash (Recent Filing)€3.94B
Total Debt (Recent Filing)€8.92B
Price to Earnings (P/E)35.4
Beta0.18
Next Earnings
Aug 11, 2026EPS Estimate
2.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.56
Shares Outstanding234,205,860
10 Day Avg. Volume7
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)-14.56
Price to Sales (P/S)0.18
P/FCF Ratio21.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€221.70Price Target Upside9.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)10.61
Revenue Forecast (FY)€242.09B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthConsistent multi-billion dollar operating and free cash flow provides durable internal funding for operations, debt repayment and capital returns. Strong cash conversion reduces reliance on external financing and supports strategic investments and buybacks over the medium term.
Scale In Pharmaceutical DistributionVery large pharma volumes and specialty distribution create structural advantages: purchasing power, entrenched customer contracts and high service dependency. This scale supports steady revenue streams and makes it hard for smaller competitors to replicate the breadth of services and logistics.
Raised Guidance And Disciplined Capital AllocationUpgraded guidance plus substantial FCF and active buybacks reflect operational improvement and prioritization of deleveraging and shareholder returns. This disciplined allocation and improving outlook increase financial resilience and support strategic execution over the next several quarters.
Bears Say
Negative Equity And LeverageNegative shareholders' equity and sizable debt meaningfully weaken the balance sheet cushion, raising refinancing and covenant risks. This structural weakness limits financial flexibility for acquisitions or cyclical shocks and elevates long-term funding cost sensitivity.
Structurally Thin MarginsVery low gross and net margins mean earnings are highly sensitive to small cost or pricing shifts. Persistent thin margins constrain reinvestment and make meeting guidance dependent on volume, mix and operational execution over the medium term.
Tariff And Regulatory UncertaintySignificant tariff exposure and unresolved refund timing create ongoing margin volatility in the GMPD segment. Regulatory unpredictability can materially alter cash flows and profitability, complicating multi-quarter planning and potentially leading to lasting headwinds if costs are sustained.
Cardinal Health News
CLH FAQ
What was Cardinal Health’s price range in the past 12 months?
Cardinal Health lowest stock price was €124.60 and its highest was €210.30 in the past 12 months.
What is Cardinal Health’s market cap?
Cardinal Health’s market cap is €47.16B.
When is Cardinal Health’s upcoming earnings report date?
Cardinal Health’s upcoming earnings report date is Aug 11, 2026 which is in 13 days.
How were Cardinal Health’s earnings last quarter?
Cardinal Health released its earnings results on Apr 30, 2026. The company reported €2.783 earnings per share for the quarter, beating the consensus estimate of €2.454 by €0.329.
Is Cardinal Health overvalued?
According to Wall Street analysts Cardinal Health’s price is currently Undervalued.
Does Cardinal Health pay dividends?
Cardinal Health does not currently pay dividends.
What is Cardinal Health’s EPS estimate?
Cardinal Health’s EPS estimate is 2.12.
How many shares outstanding does Cardinal Health have?
Cardinal Health has 234,205,860 shares outstanding.
What happened to Cardinal Health’s price movement after its last earnings report?
Cardinal Health reported an EPS of €2.783 in its last earnings report, beating expectations of €2.454. Following the earnings report the stock price went down -1.057%.
Which hedge fund is a major shareholder of Cardinal Health?
Currently, no hedge funds are holding shares in DE:CLH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardinal Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€221.70 (9.54% Upside)
€221.70 (9.54% Upside)
Blogger Sentiment
Bullish
DE:CLH Sentiment 92%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.56%
12-Months-Change
Fundamentals
Return on Equity
0.89%
Trailing 12-Months
Asset Growth
13.67%
Trailing 12-Months
Company Description
Cardinal Health
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
CLH Company Deck
CLH Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted broad-based operational strength: solid top-line growth, outsized EPS improvement, robust free cash flow generation, meaningful outperformance in Specialty and other growth businesses, and a raised, narrowed FY26 outlook. Challenges noted include a $184M goodwill impairment for Navista, tariff-related pressure in the GMPD business with uncertain refunds (paid ~ $200M to date), higher headline SG&A and rising interest costs, and revenue mix headwinds from IRA/WAC adjustments and GLP-1 moderation. On balance the company emphasized durable fundamentals, disciplined capital deployment (including $1B of buybacks), successful integration of acquisitions and confidence in long-term targets.View all DE:CLH earnings summariesCLH Revenue Breakdown
91.94% Pharmaceutical and Specialty Solutions
5.68% Global Medical Products and Distribution
2.42% Other
-0.04% Corporate

CLH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€221.70
▲(9.54% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month










